The European Journal of Health Economics

2002 - 2020

Current editor(s): J.-M.G.v.d. Schulenburg

From:
Springer
Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ)
Contact information at EDIRC.
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

Access Statistics for this journal.
Track citations for all items by RSS feed
Is something missing from the series or not right? See the RePEc data check for the archive and series.

Volume 21, issue 7, 2020

Once we have it, will we use it? A European survey on willingness to be vaccinated against COVID-19 pp. 977-982

Sebastian Neumann-Böhme, Nirosha Elsem Varghese, Iryna Sabat, Pedro Pita Barros, Werner Brouwer, Job Exel, Jonas Schreyögg and Tom Stargardt

Discrete choice experiments to generate utility values for multi-attribute utility instruments: a systematic review of methods pp. 983-992

Mina Bahrampour, Joshua Byrnes, Richard Norman, Paul A. Scuffham and Martin Downes

Cost-effectiveness of biennial screening for diabetes related retinopathy in people with type 1 and type 2 diabetes compared to annual screening pp. 993-1002

Rebecca L. Thomas, Thomas G. Winfield, Matthew Prettyjohns, Frank D. Dunstan, Wai-Yee Cheung, Philippa M. Anderson, Rajesh Peter, Stephen D. Luzio and David R. Owens

Patterns of care and cost profiles of women with breast cancer in Italy: EPICOST study based on real world data pp. 1003-1013

Silvia Francisci, Stefano Guzzinati, Giulia Capodaglio, Daniela Pierannunzio, Sandra Mallone, Andrea Tavilla, Tania Lopez, Susanna Busco, Walter Mazzucco, Catia Angiolini, Manuel Zorzi, Diego Serraino, Alessandro Barchielli, Mario Fusco, Fabrizio Stracci, Fortunato Bianconi, Massimo Rugge, Silvia Iacovacci, Antonio Giampiero Russo, Rosanna Cusimano and Anna Gigli

Quantifying the economic impact of caregiving for Duchenne muscular dystrophy (DMD) in Spain pp. 1015-1023

David Flores, María P. Ribate, Marisol Montolio, Feliciano J. Ramos, Manuel Gómez and Cristina B. García

Impacts of air pollution on health: evidence from longitudinal cohort data of patients with cardiovascular diseases pp. 1025-1038

Clifford Afoakwah, Son Nghiem, Paul Scuffham, Quan Huynh, Tom Marwick and Joshua Byrnes

Measuring intangible cost-of-morbidity due to substance dependence: implications of using alternative preference-based instruments pp. 1039-1048

Bruno Casal, Eva Rodríguez-Míguez and Berta Rivera

Predictors of negotiated prices for new drugs in Germany pp. 1049-1057

Afschin Gandjour, Sofia Schüßler, Thomas Hammerschmidt and Charalabos-Markos Dintsios

Modeling Personalized Adjuvant TreaTment in EaRly stage coloN cancer (PATTERN) pp. 1059-1073

Gabrielle Jongeneel, Marjolein J. E. Greuter, Felice N. Erning, Miriam Koopman, Jan P. Medema, Raju Kandimalla, Ajay Goel, Luis Bujanda, Gerrit A. Meijer, Remond J. A. Fijneman, Martijn G. H. Oijen, Jan Ijzermans, Cornelis J. A. Punt, Geraldine R. Vink and Veerle M. H. Coupé

The excess economic burden of mental disorders: findings from a cross-sectional prevalence survey in Austria pp. 1075-1089

Agata Łaszewska, Johannes Wancata, Rebecca Jahn and Judit Simon

An exploration of methods for obtaining 0 = dead anchors for latent scale EQ-5D-Y values pp. 1091-1103

Koonal Shah, Juan Manuel Ramos-Goñi, Simone Kreimeier and Nancy Devlin

Cost-utility analysis of inotuzumab ozogamicin for relapsed or refractory B cell acute lymphoblastic leukemia from the perspective of Taiwan’s health care system pp. 1105-1116

Tsung-Ying Lee, Hsuan-Ying Chen, Tsai-Yun Chen, Sin-Syue Li, Wei-Tse Fang, Yao-Chun Wen, Yu-Wen Lo and Huang-Tz Ou

Volume 21, issue 6, 2020

Historical evidence for economic effects of COVID-19 pp. 817-823

Rahmiye Figen Ceylan, Burhan Ozkan and Esra Mulazimogullari

Cost-effectiveness of a non-pharmacological treatment vs. “care as usual” in day care centers for community-dwelling older people with cognitive impairment: results from the German randomized controlled DeTaMAKS-trial pp. 825-844

Kathrin Steinbeisser, Larissa Schwarzkopf, Elmar Graessel and Hildegard Seidl

A novel method for predicting the budget impact of innovative medicines: validation study for oncolytics pp. 845-853

Joost W. Geenen, Svetlana V. Belitser, Rick A. Vreman, Martijn Bloois, Olaf H. Klungel, Cornelis Boersma and Anke M. Hövels

The pass-through of alcohol excise taxes to prices in OECD countries pp. 855-867

Ce Shang, Anh Ngo and Frank J. Chaloupka

Health-related quality of life in elderly people with hypertension and the estimation of minimally important difference using EQ-5D-5L in Hong Kong SAR, China pp. 869-879

Eliza Lai Yi Wong, Richard Huan Xu and Annie Wai Ling Cheung

Determination of the target population in early benefit assessments in Germany: challenges for non-small-cell lung cancer pp. 881-893

C. Thoren, C. Balg, J. Gibbert, S. Mostardt, M. Ripoll, D. Schierbaum, S. Schiller and A. Schwalm

A retrospective analysis of budget impact models submitted to the National Centre for Pharmacoeconomics in Ireland pp. 895-901

Felicity Lamrock, Laura McCullagh, Lesley Tilson and Michael Barry

Does linear equating improve prediction in mapping? Crosswalking MacNew onto EQ-5D-5L value sets pp. 903-915

Admassu N. Lamu

How expensive are post-traumatic stress disorders? Estimating incremental health care and economic costs on anonymised claims data pp. 917-930

Tim Bothe, Josephine Jacob, Christoph Kröger and Jochen Walker

Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations pp. 931-943

Lotte Westerink, Jelmer L. J. Nicolai, Carl Samuelsen, Hans J. M. Smit, Pieter E. Postmus, Ingolf Griebsch and Maarten J. Postma

The effect of time to death on health care expenditures: taking into account the endogeneity and right censoring of time to death pp. 945-962

Christophe Kolodziejczyk

Lifetime cost of unilateral cochlear implants in adults: a Monte Carlo simulation pp. 963-975

Christin Thum, Thomas Lenarz, Anke Lesinski-Schiedat and Steffen Fleßa

Volume 21, issue 5, 2020

Modelling Covid-19 under uncertainty: what can we expect? pp. 665-668

Meimei Wang and Steffen Flessa

Corruption in public health and its effects on the economic growth of Brazilian municipalities pp. 669-687

Eduarda Machoski and Jevuks Matheus Araujo

Are quality-adjusted medical prices declining for chronic disease? Evidence from diabetes care in four health systems pp. 689-702

Karen Eggleston, Brian K. Chen, Chih-Hung Chen, Ying Isabel Chen, Talitha Feenstra, Toshiaki Iizuka, Janet Tin Kei Lam, Gabriel M. Leung, Jui-fen Rachel Lu, Beatriz Rodriguez-Sanchez, Jeroen N. Struijs, Jianchao Quan and Joseph Newhouse

Improving access to services for psychotic patients: does implementing a waiting time target make a difference pp. 703-716

Anika Kreutzberg and Rowena Jacobs

Is the whole larger than the sum of its parts? Impact of missing data imputation in economic evaluation conducted alongside randomized controlled trials pp. 717-728

Bernhard Michalowsky, Wolfgang Hoffmann, Kevin Kennedy and Feng Xie

Health-related quality of life and health utilities in insulin-treated type 2 diabetes: the impact of related comorbidities/complications pp. 729-743

John Yfantopoulos and Athanasios Chantzaras

The Amsterdam Wrist Rules: how much money can they save? pp. 745-750

Marjolein A. M. Mulders, Monique M. J. Walenkamp, Nico L. Sosef, Frank Ouwehand, Romuald van Velde, J. Carel Goslings and Niels W. L. Schep

How does the integration of collaborative care elements in a gatekeeping system affect the costs for mental health care in Germany? pp. 751-761

Alexander Engels, Katrin Christiane Reber, Julia Luise Magaard, Martin Härter, Sabine Hawighorst-Knapstein, Ariane Chaudhuri, Christian Brettschneider and Hans-Helmut König

Willingness to pay for an early warning system for infectious diseases pp. 763-773

Sebastian Himmler, Job Exel, Meg Perry-Duxbury and Werner Brouwer

Incidence and costs of hospitalized adult influenza patients in The Netherlands: a retrospective observational study pp. 775-785

Sierk D. Marbus, Valentijn A. Schweitzer, Geert H. Groeneveld, Jan J. Oosterheert, Peter M. Schneeberger, Wim Hoek, Jaap T. Dissel, Arianne B. Gageldonk-Lafeber and Marie-Josée Mangen

Transforming discrete choice experiment latent scale values for EQ-5D-3L using the visual analogue scale pp. 787-800

Edward J. D. Webb, John O’Dwyer, David Meads, Paul Kind and Penny Wright

Healthcare expenditure and carbon footprint in the USA: evidence from hidden cointegration approach pp. 801-811

Murat Gündüz

Reply to the comment on “Trends in rates of orthopedic surgery in Germany: the good, the bad, the ugly.” pp. 813-814

Natalie Baier, Lisa-Marie Sax and Leonie Sundmacher

Correction to: Defensive medicine in Europe: a ‘full circle’? pp. 815-815

Livio Garattini and Anna Padula

Volume 21, issue 4, 2020

Defensive medicine in Europe: a ‘full circle’? pp. 477-482

Livio Garattini and Anna Padula

Low risk, high reward? Repeated competitive biddings with multiple winners in health care pp. 483-500

Visa Pitkänen, Signe Jauhiainen and Ismo Linnosmaa

A vision ‘bolt-on’ increases the responsiveness of EQ-5D: preliminary evidence from a study of cataract surgery pp. 501-511

Mihir Gandhi, Marcus Ang, Kelvin Teo, Chee Wai Wong, Yvonne Chung-Hsi Wei, Rachel Lee-Yin Tan, Mathieu F. Janssen and Nan Luo

Incorporating self-reported health measures in risk equalization through constrained regression pp. 513-528

A. A. Withagen-Koster, R. C. Kleef and F. Eijkenaar

A general framework for classifying costing methods for economic evaluation of health care pp. 529-542

Zuzana Špacírová, David Epstein, Leticia García-Mochón, Joan Rovira, Antonio Olry de Labry Lima and Jaime Espín

Cost-effectiveness of midostaurin in the treatment of newly diagnosed FLT3-mutated acute myeloid leukemia in France pp. 543-555

Gabriel Tremblay, Clemence Cariou, Christian Recher, Mike Dolph, Patricia Brandt, Anne-Sandrine Blanc and Anna Forsythe

Early cost-utility analysis of tissue-engineered heart valves compared to bioprostheses in the aortic position in elderly patients pp. 557-572

Simone A. Huygens, Isaac Corro Ramos, Carlijn V. C. Bouten, Jolanda Kluin, Shih Ting Chiu, Gary L. Grunkemeier, Johanna J. M. Takkenberg and Maureen P. M. H. Rutten- van Mölken

Biases in health expectancies due to educational differences in survey participation of older Europeans: It’s worth weighting for pp. 573-605

Sonja Spitzer

Patients with coronary artery disease after acute myocardial infarction: effects of continuous enrollment in a structured Disease Management Program on adherence to guideline-recommended medication, health care expenditures, and survival pp. 607-619

Florian Kirsch, Christian Becker, Anja Schramm, Werner Maier and Reiner Leidl

Does the use of health technology assessment have an impact on the utilisation of health care resources? Evidence from two European countries pp. 621-634

B. Corbacho, M. Drummond, Rita Santos, E. Jones, J. M. Borràs, J. Mestre-Ferrandiz, J. Espín, N. Henry and A. Prat

Cost of poor health to the labour market returns to education in Australia: another pathway for socio-economic inequality pp. 635-648

Tinh Doan, Lyndall Strazdins and Liana Leach

Interchangeability of the EQ-5D and the SF-6D, and comparison of their psychometric properties in a spinal postoperative Spanish population pp. 649-662

Carmen Selva-Sevilla, Paula Ferrara and Manuel Gerónimo-Pardo

Trends in rates of orthopedic surgery in Germany: the good, the bad, and the ugly pp. 663-664

Afschin Gandjour

Volume 21, issue 3, 2020

Advanced therapy medicinal products: value judgement and ethical evaluation in health technology assessment pp. 311-320

Elisabete Gonçalves

Survival and costs of colorectal cancer treatment and effects of changing treatment strategies: a model approach pp. 321-334

Paal Joranger, Arild Nesbakken, Halfdan Sorbye, Geir Hoff, Arne Oshaug and Eline Aas

Cost-effectiveness analysis of the Neuropad device as a screening tool for early diabetic peripheral neuropathy pp. 335-349

B. Rodríguez-Sánchez, L. M. Peña-Longobardo and A. J. Sinclair

Unfolding the relationship between mortality, economic fluctuations, and health in Italy pp. 351-362

Maddalena Cavicchioli and Barbara Pistoresi

The societal monetary value of a QALY associated with EQ-5D-3L health gains pp. 363-379

Laura Vallejo-Torres, Borja García-Lorenzo, Oliver Rivero-Arias and José Luis Pinto-Prades

Non-compensatory aggregation method to measure social and material deprivation in an urban area: relationship with premature mortality pp. 381-396

Carolina Bruzzi, Enrico Ivaldi and Stefano Landi

Health state utilities associated with treatment for transfusion-dependent β-thalassemia pp. 397-407

Louis S. Matza, L. Clark Paramore, Katie D. Stewart, Hayley Karn, Minesh Jobanputra and Andrew C. Dietz

Austerity, healthcare provision, and health outcomes in Spain pp. 409-423

Cristina Borra, Jerònia Pons-Pons and Margarita Vilar-Rodríguez

Once bitten, twice shy? Lessons learned from an experiment to liberalize price regulations for dental care pp. 425-436

Anna-Lena Trescher, Stefan Listl, Onno Galien, Frank Gabel and Olivier Kalmus

Cost-effectiveness and budget impact of the microprocessor-controlled knee C-Leg in transfemoral amputees with and without diabetes mellitus pp. 437-449

Alexander Kuhlmann, Henning Krüger, Susanne Seidinger and Andreas Hahn

Healthcare costs associated with breast cancer in Germany: a claims data analysis pp. 451-464

Kristine Kreis, Marika Plöthner, Torben Schmidt, Richard Seufert, Katharina Schreeb, Veronika Jahndel, Sylke Maas, Alexander Kuhlmann, Jan Zeidler and Anja Schramm

A comparison of individual and collective decision making for standard gamble and time trade-off pp. 465-473

Arthur Attema, Han Bleichrodt, Olivier l’Haridon and Stefan A. Lipman

Correction to: Cost–consequence analysis of fluticasone furoate/vilanterol for asthma management in Spain: an analysis based on the Salford Lung Study in asthma pp. 475-475

Laura Amanda Vallejo-Aparicio, Jesús Molina, Iñigo Ojanguren, Ana Viejo Casas, Alicia Huerta and Henrik Svedsater

Volume 21, issue 2, 2020

Defensive medicine in Europe: a ‘full circle’? pp. 165-170

Livio Garattini and Anna Padula

Measuring horizontal inequity in healthcare utilisation: a review of methodological developments and debates pp. 171-180

Mohammad Habibullah Pulok, Kees Gool, Mohammad Hajizadeh, Sara Allin and Jane Hall

The economic burden of chronic obstructive pulmonary disease (COPD) in Europe: results from a systematic review of the literature pp. 181-194

Anees ur Rehman, Mohamed Azmi Ahmad Hassali, Sohail Ayaz Muhammad, Sabariah Noor Harun, Shahid Shah and Sameen Abbas

Corruption and health outcomes within an economic and cultural framework pp. 195-207

Monica Violeta Achim, Viorela Ligia Văidean and Sorin Nicolae Borlea

Why are there long waits at English emergency departments? pp. 209-218

James Gaughan, Panagiotis Kasteridis, Anne Mason and Andrew Street

Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data pp. 219-233

M. Campioni, I. Agirrezabal, R. Hajek, J. Minarik, L. Pour, I. Spicka, S. Gonzalez-McQuire, P. Jandova and V. Maisnar

The contribution of real-world evidence to cost-effectiveness analysis: case study of Dabigatran etexilate in France pp. 235-249

Gérard de Pouvourville, Patrick Blin and Pierre Karam

The company you keep: health behavior among work peers pp. 251-259

Gerald J. Pruckner, Thomas Schober and Katrin Zocher

The impact of prescription drug co-payments for publicly insured families pp. 261-274

Gretta Mohan and Anne Nolan

How averse are the UK general public to inequalities in health between socioeconomic groups? A systematic review pp. 275-285

Simon McNamara, John Holmes, Abigail K. Stevely and Aki Tsuchiya

Cognitive ability and teen smoking pp. 287-296

Hendrik Jürges and Sophie-Charlotte Meyer

Economic evaluation of meningococcal vaccines: considerations for the future pp. 297-309

Hannah Christensen, Hareth Al-Janabi, Pierre Levy, Maarten J. Postma, David E. Bloom, Paolo Landa, Oliver Damm, David M. Salisbury, Javier Diez-Domingo, Adrian K. Towse, Paula Lorgelly, Koonal Shah, Karla Hernandez-Villafuerte, Vinny Smith, Linda Glennie, Claire Wright, Laura York and Raymond Farkouh

Volume 21, issue 1, 2020

HTA for pharmaceuticals in Europe: will the mountain deliver a mouse? pp. 1-5

Livio Garattini and Anna Padula

Cost–consequence analysis of fluticasone furoate/vilanterol for asthma management in Spain: an analysis based on the Salford Lung Study in asthma pp. 7-17

Laura Amanda Vallejo-Aparicio, Jesús Molina, Iñigo Ojanguren, Ana Viejo Casas, Alicia Huerta and Henrik Svedsater

The income gradient and child mental health in Australia: does it vary by assessors? pp. 19-36

Rasheda Khanam, Son Nghiem and Maisha Rahman

Speeding up the clinical pathways by accessing emergency departments pp. 37-44

Rosella Levaggi, Marcello Montefiori and Luca Persico

The value of persistence in treatment with subcutaneous TNF-alpha inhibitors for ankylosing spondylitis pp. 45-54

Axel Svedbom, Johan Dalén, Moa Ivergård, Rebekah H. Borse, Christopher M. Black, Karin Luttropp and Sumesh Kachroo

Provision of health care services and regional diversity in Germany: insights from a Bayesian health frontier analysis with spatial dependencies pp. 55-71

Rouven Edgar Haschka, Katharina Schley and Helmut Herwartz

A cost-utility analysis of phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction pp. 73-84

Svenn Alexander Hansen, Eline Aas and Oddvar Solli

Inefficiencies in a healthcare system with a regulatory split of power: a spatial panel data analysis of avoidable hospitalisations in Austria pp. 85-104

Anna-Theresa Renner

Global budget versus cost ceiling: a natural experiment in hospital payment reform in the Netherlands pp. 105-114

Katalin Gaspar, France Portrait, Eric Hijden and Xander Koolman

Economic burden of blindness and visual impairment in Germany from a societal perspective: a cost-of-illness study pp. 115-127

Yuliya Chuvarayan, Robert P. Finger and Juliane Köberlein-Neu

Does external reference pricing deliver what it promises? Evidence on its impact at national level pp. 129-151

Panos Kanavos, Anna-Maria Fontrier, Jennifer Gill and Olina Efthymiadou

Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations pp. 153-164

Marscha S. Holleman, Maiwenn J. Al, Remziye Zaim, Harry J. M. Groen and Carin A. Uyl- de Groot